Lisata Therapeutics (LSTA) Stock Price, News & Analysis

Company Overview

Lisata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company’s approach is designed to improve the delivery and effectiveness of cancer treatments by targeting the tumor microenvironment, which can limit the penetration of medicines into tumors.

Lisata’s lead investigational product is certepetide, formerly known as CEND-1. Certepetide is a tumor-penetrating peptide intended to selectively home to tumor tissue and temporarily modify the tumor microenvironment, potentially helping co-administered anticancer therapies reach cancer cells more effectively. The company is evaluating the therapy in combination with established cancer treatments across several solid-tumor indications.

The company was previously known as Cend Therapeutics and adopted the Lisata Therapeutics name in 2022. Lisata is headquartered in San Diego, California, and conducts its research and clinical development activities through collaborations and clinical studies in the United States and other regions. The company is led by President and Chief Executive Officer David J. Mazzo, Ph.D.

Key Stats

• Today's Range: $1.15 to $1.30
• 50-Day Range: $0.99 to $1.90
• 52-Week Range: $0.96 to $5.07
• Volume: 119,688 shs
• Average Volume: 184,710 shs
• Market Capitalization: $13.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Lisata Therapeutics Stock Analysis - MarketRank™

Lisata Therapeutics scored higher than 13% of companies evaluated by MarketBeat, and ranked 848th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Lisata Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Lisata Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lisata Therapeutics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lisata Therapeutics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lisata Therapeutics has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.35% of the float of Lisata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lisata Therapeutics has a short interest ratio ("days to cover") of 0.58, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lisata Therapeutics has recently increased by 18.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lisata Therapeutics does not currently pay a dividend.

Dividend Growth

Lisata Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.15

News Sentiment

Lisata Therapeutics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Lisata Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.40% of the stock of Lisata Therapeutics is held by insiders.

Percentage Held by Institutions

8.94% of the stock of Lisata Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 11/12/2026
• Next Earnings (Estimated): 11/12/2026
• Jefferies Global Healthcare Conference: 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LSTA
• CIK: 320017
• Web: www.lisata.com
• Phone: (908) 229-2590
• Fax: 646-514-7787
• Employees: 21
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): ($1.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.59 million
• Net Margins: N/A
• Pretax Margin: -15,008.00%
• Return on Equity: -116.08%
• Return on Assets: -90.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.69
• Quick Ratio: 3.69

Sales & Book Value

• Annual Sales: $100 thousand
• Price / Sales: 138.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.66 per share
• Price / Book: 0.77

Miscellaneous

• Outstanding Shares: 10,804,000
• Free Float: 9,896,000
• Market Cap: $13.83 million
• Optionable: Not Optionable
• Beta: 1.04